Unknown

Dataset Information

0

Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.


ABSTRACT: BACKGROUND:Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma. Emerging techniques to engineer T-cell receptors (TCRs) or chimeric antigen receptors (CARs) using lymphocytes from peripheral blood may offer new tactics in ACT. METHODS:We reviewed the literature to provide a synopsis on the development and clinical trial results of ACT, as well as the future outlook for using ACT in patients with metastatic melanoma. RESULTS:ACT with TILs as part of a lymphodepleting regimen has been shown in clinical trials to cause objective clinical responses in approximately 40% to 72% of patients with metastatic melanoma, with up to 40% of those patients experiencing complete responses lasting up to 7 years ongoing. Pilot trials using TCR-engineered cells against melanoma-associated antigens MART-1 and gp100 and the cancer-testis antigen NY-ESO-1 have shown clinical responses in patients with melanoma. CAR cells directed against melanoma have been tested only in preclinical models; however, CAR cells targeting other histologies such as lymphoma have elicited antitumor responses in patients. CONCLUSIONS:An example of state-of-the-art personalized medicine, ACT is a potentially curative therapy for patients with metastatic melanoma. Ongoing trials aiming to simplify the regimens may allow a broader range of patients to be treated and enable ACT to be offered by academic cancer centers.

SUBMITTER: Phan GQ 

PROVIDER: S-EPMC6322197 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

Phan Giao Q GQ   Rosenberg Steven A SA  

Cancer control : journal of the Moffitt Cancer Center 20131001 4


<h4>Background</h4>Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma  ...[more]

Similar Datasets

| S-EPMC3382856 | biostudies-literature
| S-EPMC3587427 | biostudies-literature
| S-EPMC4070853 | biostudies-literature
| S-EPMC8423703 | biostudies-literature
| S-EPMC6028054 | biostudies-literature
| S-EPMC6276301 | biostudies-literature
| S-EPMC3131487 | biostudies-literature
| S-EPMC3720863 | biostudies-literature
| S-EPMC9288495 | biostudies-literature
| S-EPMC3667909 | biostudies-literature